华尔街俱乐部资本市场资讯服务

华尔街俱乐部近期将推出实时美股、指数资讯服务，信息源自Bloomberg。今后我们还将陆续推出更多中美资本市场的资讯和中概股公司动态。敬请垂注。欢迎有兴趣本栏目的企业冠名支持。

返回新闻服务主页返回中概股列表

ZLAB:US NASDAQ GM

Zai Lab Ltd

AS OF 11/22/2024 CST

26.43 USD +0.73 +2.84%

OPEN

25.24

PREV CLOSE

25.70

VOLUME

790,653

MARKET CAP

2.871B

DAY RANGE

25.16 - 26.66

52 WEEK RANGE

13.48 - 36.60

About Zai Lab Ltd

Zai Lab Limited operates as a biopharmaceutical company. The Company researches and develops therapeutic technology for antibody-based oncology, autoimmune, and infectious diseases treatments. Zai Lab also manufactures drugs in the form of capsules, injections, and liquids. Zai Lab serves patients worldwide.

SECTOR

Health Care

INDUSTRY

Health Care

SUB-INDUSTRY

Biotech & Pharma

ADDRESS

4560 Jinke Road, Building 1 4th Floor, Jinchuang Plaza Pudong, 201210 China

PHONE

86-21-6163-2588

WEBSITE

www.zailaboratory.com

Key Statistics

P/E Ratio

-2.26

1 Year Return

-6.84

Estimated P/E

-2.73(2024-12)

30 Day Avg Volume

Average Volume (30-day)

1,252,525

Shares Outstanding (M)

108.63

Dividend

Last Dividend Reported

:

Executives

Dr Ying Du PhD "Samantha" / Chairman/CEO/Co-Founder
Joshua L Smiley "Josh" / President/COO
Dr Yajing Chen PhD / Chief Financial Officer
F Ty Edmondson / Chief Legal Officer/Secretary
Dr Peter Huang PhD / Chief Scientific Officer
Jonathan Wang / Chief Business Officer
Dr Rafael G Amado / Pres & Head:Global Research & Dev
Dr Yan Shuizhong PhD "James" / COO:Global R&D
Dr Robert J Brown / Chief Medical Officer:Oncology
Andrew Zhu / Chief Commercial Officer:Greater China
Dr Ning Xu / Exec VP & Head:Clinical Operations
Christine Chiou / Sr VP/Head:Investor Relations
Dr Prista Charuworn / VP:Immunology